Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Loss of PTEN Regulator Linked to Cancer

By Biotechdaily staff writers
Posted on 25 Jun 2003
A recent study describes the electrostatic mechanism that controls the binding of the tumor-suppressing protein PTEN (phosphatase and tensin homolog on chromosome 10) to the cell membrane.

PTEN is a tumor suppressor that reverses the action of phosphoinositide 3-kinase by catalyzing the removal of the 3' phosphate of phosphoinositides. More...
"The role of PTEN is to counterbalance the action of an enzyme that induces cell growth,” explained senior author Dr. Wonhwa Cho, professor of chemistry at the University of Chicago (IL, USA; www.uic.edu). "Overactivation of the enzyme can lead to cancer. So if you lose a PTEN gene and its cellular activity, the cell goes out of control. It is like a car with an accelerator but without the brakes.”

The investigators employed surface plasmon resonance analysis and cellular microscopic analysis of green fluorescence protein-labeled PTEN to study its transport and binding within the cell. They found that phosphorylation of PTEN changed its electrostatic property. Once it switched from being electrostatically neutral to being positively charged, PTEN attached to negatively charged molecules on the cell membrane. These findings were published June 13, 2003, in the online edition of the Proceedings of the National Academy of Science.

Mutations resulting in the loss of PTEN regulation have been linked to various cancers, including glioblastoma, endometrial carcinoma, and a cancer-prone condition called Cowden disease.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.